Reading Performance in Patients With Acrysof IQ Vivity Versus Acrysof IQ

Sponsor
Vienna Institute for Research in Ocular Surgery (Other)
Overall Status
Recruiting
CT.gov ID
NCT05194657
Collaborator
(none)
68
1
2
24
2.8

Study Details

Study Description

Brief Summary

Comparison of the visual function and reading performance between the Acrysof IQ Vivity IOL, an EDOF IOL, and the monofocal Acrysof IQ.

Condition or Disease Intervention/Treatment Phase
  • Device: enhanced depth of focus IOL
  • Device: monofocal IOL
N/A

Detailed Description

With increasing demands of patients concerning their visual function after cataract surgery, a variety of advanced technology intraocular lenses (IOL) have become available in the last years. Various developments aim at a reduced spectacle independence for patients after cataract or refractive lens surgery.

Novel technology for providing an extended depth of focus (EDOF) has been developed to account for unmet needs of patients. A novel EDOF IOL, the Acrysof IQ Vivity, has two surface transition elements that work simultaneously by stretching and shifting the wavefront to create a continuous extended focal range instead of multiple focal points.

To assess the performance of such an IOL technology, most studies assess visual acuity at different distances from far, to intermediate up to near. Since most activites with digital devices implicate reading, it is not surprising that reading difficulty is the most common complaint among individuals experiencing visual disturbances with multifocal designs.

Reading ability is usually evaluated using various reading tests that assess reading speed and reading acuity defined as the print size that can stell be read with sufficient speed. However, one of the fundamental problems of these tests is that reading speed is also influenced by the average amount of time that a patient reads as well as the language of the text, whether it is the first or second language.

A novel method to analyse reading performance that appears to be more objective and less reliant on the cognitive abilities of the patient is the observation of the reading pattern using a high-speed eye-tracking system that analyses eye fixations during the reading test. In previous studies we have seen that several aspects of this reading patter, i.e. fixation duration and fixation frequency, appear to correlate with the reading performance overall and can be differentially used to discriminate between cognitive and visuo-motor processing.

Hence, the aim of this study is to assess the visual function and reading performance with an EDOF IOL (Acrysof IQ Vivity) compared to a standard monofocal IOL (Acrysof IQ).

136 eyes of 68 patients will be included into this study. According to the randomization, 34 patients will be implanted with the Acrysof IQ Vivity in both eyes and the other 34 patients will be implanted with the Acrysof IQ in both eyes. A follow-up examination will be performed at 3 months postoperative. During this visit a slitlamp examination, biometry and tomography of the eye, refraction and visual acuity assessment, an OCT examination, a retroillumination photogrypha, reading speed analysis and halometry will be performed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
68 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Assessment of Reading Performance in Patients With Acrysof IQ Vivity Toric or Non-toric vs Monofocal Acrysof IQ Toric or Non-toric IOL
Actual Study Start Date :
Jan 3, 2022
Anticipated Primary Completion Date :
Jan 3, 2023
Anticipated Study Completion Date :
Jan 3, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acrysof IQ Vivity

Patient will receive the enhanced depth of focus IOL during cataract surgery

Device: enhanced depth of focus IOL
Acrysof IQ Vivity, enhanced depth of focus IOL

Experimental: Acrysof IQ

Patiet will receive the monofocal IOL during cataract surgery

Device: monofocal IOL
Acrysof IQ, monofocal IOL

Outcome Measures

Primary Outcome Measures

  1. Reading speed [24 months]

    reading speed will be assessed with the Eyetracker device at 66 centimetres and will be compared between the EDOF IOL and the monofocal IOL

Secondary Outcome Measures

  1. Visual acuity [24 months]

    Visual acuity will be assessed using the ETDRS charts and will be compared between the EDOF IOLs and the monofocal IOLs

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 105 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Cataract

  • Stereopsis

  • age 21 and older

  • regular corneal astigmatism of up to 3.0 D

  • written informed consent prior to surgery

  • normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

  • availability, willingness and sufficient cognitive awareness to comply with examination procedures

  • german as mother-tongue

  • calculated IOL power needed is below 15.0 D or above 25.0 D (no high myopia or high hypermetropia will be recruited)

Exclusion Criteria:
  • relevant other ophthalmic diseases such as: pseudoexfoliation, glaucoma, traumatic cataract, corneal scars, and other co-morbidity that could affect capsule bag stability (e.g. Marfan syndrome) or retinal diseases affecting visual acuity (AMD, Macular Pucker, post-operative macular edema...)

  • amblyopia

  • contact lenses

  • irregular corneal astigmatism on corneal topography

  • postoperative subjective refraction smaller/ higher than or 0.75 D

  • pregnancy (pregnancy test will be taken preoperatively in women of reproductive age)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna Vienna Austria 1140

Sponsors and Collaborators

  • Vienna Institute for Research in Ocular Surgery

Investigators

  • Principal Investigator: Oliver Findl, MD, Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
ClinicalTrials.gov Identifier:
NCT05194657
Other Study ID Numbers:
  • Vivity
First Posted:
Jan 18, 2022
Last Update Posted:
Jan 18, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2022